FI20075971A - Komposition för behandling av steril inflammation - Google Patents

Komposition för behandling av steril inflammation Download PDF

Info

Publication number
FI20075971A
FI20075971A FI20075971A FI20075971A FI20075971A FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A FI20075971 A FI 20075971A
Authority
FI
Finland
Prior art keywords
sterile
composition
treating
pharmaceutical composition
treatment
Prior art date
Application number
FI20075971A
Other languages
English (en)
Finnish (fi)
Other versions
FI20075971A0 (sv
FI122450B (sv
Inventor
Thomas Tallberg
Original Assignee
Helsingfors Institution Foer B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingfors Institution Foer B filed Critical Helsingfors Institution Foer B
Publication of FI20075971A0 publication Critical patent/FI20075971A0/sv
Priority to FI20075971A priority Critical patent/FI122450B/sv
Priority to CN2008801231858A priority patent/CN101917983B/zh
Priority to US12/810,150 priority patent/US20100291235A1/en
Priority to PCT/FI2008/050750 priority patent/WO2009083643A2/en
Priority to NZ597977A priority patent/NZ597977A/xx
Priority to KR1020107016810A priority patent/KR20100103856A/ko
Priority to PL08868549T priority patent/PL2234611T3/pl
Priority to DE08868549T priority patent/DE08868549T1/de
Priority to EP08868549A priority patent/EP2234611B1/en
Priority to NZ597976A priority patent/NZ597976A/xx
Priority to ES08868549T priority patent/ES2381690T3/es
Priority to AU2008345508A priority patent/AU2008345508B2/en
Priority to DK08868549.0T priority patent/DK2234611T3/da
Priority to BRPI0821919-2A priority patent/BRPI0821919A2/pt
Priority to JP2010540153A priority patent/JP5378406B2/ja
Priority to AT08868549T priority patent/ATE544450T1/de
Priority to NZ586496A priority patent/NZ586496A/en
Priority to RU2010130889/15A priority patent/RU2462244C2/ru
Publication of FI20075971A publication Critical patent/FI20075971A/sv
Priority to IL206596A priority patent/IL206596A0/en
Priority to HK10110064.8A priority patent/HK1143539A1/xx
Application granted granted Critical
Publication of FI122450B publication Critical patent/FI122450B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FI20075971A 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation FI122450B (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FI20075971A FI122450B (sv) 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation
ES08868549T ES2381690T3 (es) 2007-12-28 2008-12-17 Composición para tratar inflamación estéril
DK08868549.0T DK2234611T3 (da) 2007-12-28 2008-12-17 Sammensætning til behandling af steril inflammation
PCT/FI2008/050750 WO2009083643A2 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
NZ597977A NZ597977A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
KR1020107016810A KR20100103856A (ko) 2007-12-28 2008-12-17 무균성 염증을 치료하기 위한 조성물
PL08868549T PL2234611T3 (pl) 2007-12-28 2008-12-17 Kompozycja do leczenia jałowego zapalenia
DE08868549T DE08868549T1 (de) 2007-12-28 2008-12-17 Zusammensetzung zur behandlung steriler entzündungen
EP08868549A EP2234611B1 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
NZ597976A NZ597976A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
CN2008801231858A CN101917983B (zh) 2007-12-28 2008-12-17 用于治疗无菌性炎症的组合物
AU2008345508A AU2008345508B2 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
US12/810,150 US20100291235A1 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
BRPI0821919-2A BRPI0821919A2 (pt) 2007-12-28 2008-12-17 Composição para tratamento de inflamação não-infecciosa
JP2010540153A JP5378406B2 (ja) 2007-12-28 2008-12-17 無菌性炎症の治療用組成物
AT08868549T ATE544450T1 (de) 2007-12-28 2008-12-17 Zusammensetzung zur behandlung steriler entzündungen
NZ586496A NZ586496A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
RU2010130889/15A RU2462244C2 (ru) 2007-12-28 2008-12-17 Композиция для лечения неинфекционного воспаления
IL206596A IL206596A0 (en) 2007-12-28 2010-06-24 Composition for treating sterile inflammation
HK10110064.8A HK1143539A1 (en) 2007-12-28 2010-10-26 Composition for treating sterile inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20075971A FI122450B (sv) 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation
FI20075971 2007-12-28

Publications (3)

Publication Number Publication Date
FI20075971A0 FI20075971A0 (sv) 2007-12-28
FI20075971A true FI20075971A (sv) 2009-06-29
FI122450B FI122450B (sv) 2012-01-31

Family

ID=38951666

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075971A FI122450B (sv) 2007-12-28 2007-12-28 Komposition för behandling av steril inflammation

Country Status (18)

Country Link
US (1) US20100291235A1 (sv)
EP (1) EP2234611B1 (sv)
JP (1) JP5378406B2 (sv)
KR (1) KR20100103856A (sv)
CN (1) CN101917983B (sv)
AT (1) ATE544450T1 (sv)
AU (1) AU2008345508B2 (sv)
BR (1) BRPI0821919A2 (sv)
DE (1) DE08868549T1 (sv)
DK (1) DK2234611T3 (sv)
ES (1) ES2381690T3 (sv)
FI (1) FI122450B (sv)
HK (1) HK1143539A1 (sv)
IL (1) IL206596A0 (sv)
NZ (3) NZ597976A (sv)
PL (1) PL2234611T3 (sv)
RU (1) RU2462244C2 (sv)
WO (1) WO2009083643A2 (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153267B (zh) * 2010-08-18 2015-07-22 高露洁-棕榄公司 口腔护理产品及其使用和制备方法
FI123756B (sv) * 2010-09-21 2013-10-31 Neurofood Ab Oy Förbättrat näringstillskott för behandling och förebyggande av cancer
JP5837315B2 (ja) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
RU2156087C1 (ru) * 1999-11-25 2000-09-20 Товарищество с ограниченной ответственностью Фирма "Электронная медицина" Биологически активная добавка
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
EP1523985B1 (en) * 2003-10-17 2010-03-10 Oy Neurofood Ab Non-radioactive strontium agent for treating cancer
FI121915B (sv) * 2004-02-06 2011-06-15 Neurofood Ab Oy Komposition för behandling av psoriasis
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
RU2308199C2 (ru) * 2005-05-13 2007-10-20 Закрытое акционерное общество "Компания "Нутритек" (ЗАО "Компания "Нутритек") Продукт энтерального питания "нутриэн гепа"

Also Published As

Publication number Publication date
IL206596A0 (en) 2010-12-30
ES2381690T3 (es) 2012-05-30
RU2010130889A (ru) 2012-02-10
DE08868549T1 (de) 2011-03-17
NZ597976A (en) 2012-08-31
FI20075971A0 (sv) 2007-12-28
NZ586496A (en) 2012-03-30
WO2009083643A2 (en) 2009-07-09
CN101917983A (zh) 2010-12-15
AU2008345508B2 (en) 2013-11-14
HK1143539A1 (en) 2011-01-07
FI122450B (sv) 2012-01-31
NZ597977A (en) 2012-08-31
AU2008345508A1 (en) 2009-07-09
JP2011507937A (ja) 2011-03-10
ATE544450T1 (de) 2012-02-15
KR20100103856A (ko) 2010-09-28
PL2234611T3 (pl) 2012-07-31
CN101917983B (zh) 2013-08-21
JP5378406B2 (ja) 2013-12-25
US20100291235A1 (en) 2010-11-18
EP2234611B1 (en) 2012-02-08
BRPI0821919A2 (pt) 2015-06-16
EP2234611A2 (en) 2010-10-06
RU2462244C2 (ru) 2012-09-27
DK2234611T3 (da) 2012-05-07
WO2009083643A3 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
AU2016216625A1 (en) Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
WO2007006307A3 (en) Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
MX2009010407A (es) Derivados fluorados de deferiprona.
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201171350A1 (ru) Замещенные ароматические соединения и их фармацевтические применения
WO2006097337A3 (en) 11β-HYDROXYSTEROID DEHYDROGENASES
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE323705T1 (de) Substituierte indolizinähnliche verbindungen und ihre verwendung
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
MX2009008174A (es) Uso de compuestos de arsenico para el tratamiento del dolor y la inflamacion.
EP4328218A3 (de) Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
TW200628473A (en) Novel heterocycles
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
GEP20125438B (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
HK1143539A1 (en) Composition for treating sterile inflammation
MX2022014925A (es) Moduladores de il-17a.
MX2022014924A (es) Moduladores de il-17a.
RU2010126868A (ru) Фармацевтическая композиция, предназначенная для лечения заболеваний центральной и периферической нервной системы сосудистого, травматического, токсического, гипоксического и аутоиммунного генеза
RU2492163C9 (ru) Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии
ATE466576T1 (de) Zusammensetzung mit l-serin, l-isoleucin, folsäure und spurenelementen zur behandlung von psoriasis

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: OY NEUROFOOD AB

Free format text: OY NEUROFOOD AB

FG Patent granted

Ref document number: 122450

Country of ref document: FI

MM Patent lapsed